REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
7.62
+0.21 (2.83%)
At close: Dec 20, 2024, 4:00 PM
7.71
+0.09 (1.18%)
After-hours: Dec 20, 2024, 7:01 PM EST
REGENXBIO Revenue
REGENXBIO had revenue of $24.20M in the quarter ending September 30, 2024, a decrease of -16.31%. This brings the company's revenue in the last twelve months to $84.33M, down -15.14% year-over-year. In the year 2023, REGENXBIO had annual revenue of $90.24M, down -19.94%.
Revenue (ttm)
$84.33M
Revenue Growth
-15.14%
P/S Ratio
4.32
Revenue / Employee
$245,137
Employees
344
Market Cap
377.53M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | 35.23M | -183.27M | -83.88% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ZimVie | 451.29M |
| AngioDynamics | 292.73M |
| Personalis | 87.49M |
| Alpha Teknova | 36.35M |
| Delcath Systems | 22.64M |
| Taysha Gene Therapies | 9.92M |
| Prime Medicine | 800.00K |
RGNX News
- 15 days ago - Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 - PRNewsWire
- 4 weeks ago - REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA - PRNewsWire
- 5 weeks ago - REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 - PRNewsWire
- 6 weeks ago - REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates - PRNewsWire
- 6 weeks ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire
- 7 weeks ago - REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track - Seeking Alpha
- 7 weeks ago - REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights - PRNewsWire